Actively Recruiting
Study of Solriamfetol for Treating Major Depressive Disorder with Excessive Daytime Sleepiness Using a Randomized Withdrawal Design
Led by Axsome Therapeutics, Inc. · Updated on 2026-10-13
508
Participants Needed
40
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of solriamfetol in adults with major depressive disorder MDD who also experience excessive daytime sleepiness EDS. This Phase 3 trial involves an open-label treatment phase followed by a randomized, double-blind withdrawal phase. The goal is to evaluate the time to relapse of depressive symptoms when continuing solriamfetol versus switching to placebo. Participants first undergo a screening period and then receive open-label solriamfetol tablets once daily. Those who respond to treatment enter a double-blind phase where they are randomly assigned to either continue solriamfetol 150 mg daily or switch to a placebo. This withdrawal period lasts up to 24 weeks or until depressive symptoms relapse. Throughout the study, participants are monitored for clinical response and relapse of symptoms. The primary outcome is the time from randomization to relapse of depressive symptoms. The study includes follow-up to assess ongoing symptoms, with a total participation duration that includes screening, treatment, randomized withdrawal, and follow-up periods.
CONDITIONS
Brief Title
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here